Nexobrid (Concentrate Of Proteolytic Enzymes Enriched In Bromelain)

Bromelain contains proteolytic enzymes that hydrolyze collagen, fibrin, and other extracellular matrix proteins within necrotic tissue. By breaking down these structural components, the concentrate selectively digests dead tissue while leaving viable dermal cells largely intact, enabling controlled debridement of burns.

The dose of Nexobrid is determined by the prescribing clinician based on the size, depth and location of the burn. A trained healthcare professional applies a measured amount of the topical concentrate to the cleaned wound for a specific exposure time, after which the area is irrigated according to the product label.

Safety data for Nexobrid in pregnancy and lactation are limited, and the product carries an unknown pregnancy category. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Nexobrid, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any required import documentation.

Nexobrid offers a non‑surgical, enzymatic alternative to traditional excision or to other topical agents such as collagenase (Santyl). Compared with surgical debridement, it can reduce operative time and preserve more viable tissue. Compared with other enzymes, bromelain’s broad proteolytic activity provides rapid, selective removal of necrotic tissue, though clinical choice depends on wound characteristics and provider experience.

Nexobrid should be stored at ambient temperature, preferably below 25 °C, in its original sealed container. Protect the product from moisture, direct sunlight and extreme temperatures. Once opened, follow the label instructions for any time‑limited use and keep the concentrate away from children and unauthorized personnel.

A qualified clinician cleans the burn wound, then applies the prescribed amount of Nexobrid topical concentrate evenly over the affected area. The product remains in contact for a defined exposure period, after which the wound is thoroughly irrigated with saline or an appropriate solution. Application is performed in a controlled clinical setting to ensure safety and efficacy.

The most serious risks include severe allergic reactions such as anaphylaxis, unintended deep tissue necrosis beyond the target area, systemic hypotension from enzyme absorption, secondary infection of the wound, and delayed healing or excessive scarring if debridement is overly aggressive. Prompt recognition and management of these events are essential.

Nexobrid is contraindicated in patients with a known hypersensitivity to bromelain or any component of the formulation. It should also be avoided on infected or heavily contaminated wounds, and in individuals where enzymatic debridement is not clinically indicated, such as those with full‑thickness burns requiring surgical excision.